Craft

Accelerate Diagnostics

Stock Price

$1.9

2024-10-29

Market Capitalization

$43.8 M

2024-10-29

Revenue

$11.7 M

FY, 2024

Accelerate Diagnostics Summary

Company Summary

Overview
Accelerate Diagnostics is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.
Type
Public
Status
Active
Founded
2004
HQ
Tucson, AZ, US | view all locations
Website
http://acceleratediagnostics.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Jack Schuler, Director

    • Jack Phillips

      Jack Phillips, President and Chief Executive Officer

      • John Patience, Chairman of the Board

        • Steve Reichling

          Steve Reichling, CFO

          LocationsView all

          2 locations detected

          • Tucson, AZ HQ

            United States

            3950 S Country Club Rd

          • Barcelona, CT

            Spain

            C. del Consell de Cent, 333, 7a

          Accelerate Diagnostics Financials

          Summary Financials

          Revenue (FY, 2024)
          $11.7M
          Gross profit (FY, 2024)
          $2.7M
          Net income (FY, 2024)
          ($50.0M)
          Cash (FY, 2024)
          $15.1M
          EBIT (FY, 2024)
          ($35.3M)
          Enterprise value
          $28.7M

          Footer menu